Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome

Table 1

Clinical and laboratory characteristics of ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome patients and healthy controls.

Assessed parameter	Ankylosing spondylitis patients	Psoriatic arthritis patients	SAPHO syndrome patients	Healthy controls
	()	()	()	()
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)
Age (years)	43.3 ± 13.2	52.0 ± 12.0	54.8 ± 12.3	48.2 ± 13.5
Sex	12 F. 49 M	39 F. 30 M	19 F. 3 M	19 F. 10 M
Disease duration (years)	10.0 (5.0, 18.0)	5.0 (2.0, 8.0)	2.0 (1.0, 4.0)	0
PASI	0.0	1.2 (0.0, 4.8)	—	0.0
BASDAI	5.72 (4.0, 7.8)	3.4 (2.3, 5.3)	3.6 (2.5, 5.0)	0
VAS pain (mm)	60.0 (40.0, 80.0)	40.0 (30.0, 60.0)	50.0 (40.0, 60.0)	0.0
CRP (mg/L)	9.93 (3.89, 17.1)	4.15 (1.85, 10.9)	4.2 (1.0, 10.6)	0.0
ESR (mm/h)	15.0 (7.0, 28.0)	13.0 (6.0, 22.0)	16.0 (6.0, 30.0)	9.4 (1.0, 26.0)
IL-23 (pg/mL)	0.3 (0.0, 2.8)	0.0 (0.0, 1.5)	0.0 (0.0, 0.3)	0.0 (0.0, 0.0)
IL-6 (pg/mL)	4.09 (1.8, 7.9)	2.83 (1.5, 6.2)	2.16 (1.0, 5.7)	1.2 (0.7, 1.5)
VEGF (pg/mL)	395.2 (220.0, 680.0)	291.4 (205.7, 652.7)	33.1 (222.5, 372.5)	300.1 (217.0, 437.6)
EGF (pg/mL)	120.0 (174.0, 186.0)	120.0 (60.0, 186.0)	126.0 (70.0, 208.0)	93.0 (45.0, 192.5)
FGFb (pg/mL)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
FGFa (pg/mL)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 24.3)	0.0 (0.0, 0.0)

Data are presented as number or mean ± standard deviation (Q1, Q3).
CRP: C-reactive protein.
EGF: epidermal growth factor.
ESR: erythrocyte sedimentation rate.
FGFa: acidic fibroblast growth factor.
FGFb: basic fibroblast growth factor.
IL-6: interleukin-6.
IL-23: interleukin-23.
: number of patients.
PASI: Psoriasis Area and Severity Index.
SD: standard deviation.
VAS pain: visual analogue scale of patient’s pain.
VEGF: vascular endothelial growth factor.